Comparative efficacy and safety of late surfactant preparations: a retrospective study

OBJECTIVE: Characterize the use, efficacy, and safety of poractant alfa and calfactant surfactants compared to beractant in preterm infants receiving late surfactant. STUDY DESIGN: We included infants <37 weeks gestational age (GA) discharged from Pediatrix Medical Group-managed neonatal intensiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Lane, Morgan D., Kishnani, Sujata, Udemadu, Obianuju, Danquah, Samuel Eshun, Treadway, Robert M., Langman, Aaliyah, Balevic, Stephen, Jackson, Wesley M., Laughon, Matthew, Hornik, Christoph P., Greenberg, Rachel G., Clark, Reese H., Zimmerman, Kanecia O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290378/
https://www.ncbi.nlm.nih.gov/pubmed/34285358
http://dx.doi.org/10.1038/s41372-021-01142-2
Descripción
Sumario:OBJECTIVE: Characterize the use, efficacy, and safety of poractant alfa and calfactant surfactants compared to beractant in preterm infants receiving late surfactant. STUDY DESIGN: We included infants <37 weeks gestational age (GA) discharged from Pediatrix Medical Group-managed neonatal intensive care units (1997–2017). Efficacy and safety outcomes of interest were analyzed. RESULTS: Of 184,770 infants administered surfactant at any time, 7846 (4.23%) received late surfactant at a median (25th, 75th percentile) PNA of 8 days (3, 22); specifically, 2976 received poractant alfa (38%), 2890 beractant (37%), and 1936 calfactant (25%). We identified no significant differences in composite efficacy or safety outcomes between surfactants in the primary analysis, but 33–36 week GA infants administered poractant alfa had significantly greater odds of developing a safety event. CONCLUSIONS: Compared to beractant, there is no evidence of overall superior efficacy or safety of poractant alfa.

Ejemplares similares